"I am primarily an adult neuro-oncologist, but I have a special interest in BRAF-mutated brain tumors. Many pleomorphic xantoastrocytomas have this BRAF mutation and I am studying the effect of targeted therapy (dabrafenib and trametinib) for these tumors, as well as the ways the tumors evade treatment.
We
published a case series of 2 adult patients with brain tumors containing the
BRAF V600 mutation and describing their prolonged responses to therapy earlier
this year (see attached). We have also opened a clinical trial to collect
tumor tissue from people who have tumors with this mutation and have taken the
targeted therapies against BRAF or MEK in the past: https://clinicaltrials.gov/ct2/show/NCT03593993 Our
goal is to study the tumors and understand WHY the treatment didn’t work (or
stopped working). We hope to develop new treatments from this that will work
for other people with brain tumors." Please feel free to share this information
on your website. I’m also happy to answer other questions regarding treatment for
brain tumors with the BRAF mutation for others, since this is an incredibly
rare (and sometimes confusing) mutation. Please
feel free to share this information on your website. I’m also happy to answer
other questions regarding treatment for brain tumors with the BRAF mutation for
others, since this is an incredibly rare (and sometimes confusing) mutation."
A continuación muestro el estudio al que hace referencia al comienzo:
Concurrent BRAF/MEK Inhibitors in BRAF V600–Mutant High-Grade Primary Brain Tumors
Karisa C. Schreck, MD, PhDa; Andrew Guajardo, MDb; Doris D.M. Lin, MD, PhDc; Charles G. Eberhart, MD, PhDb; and Stuart A. Grossman, MDd
No hay comentarios:
Publicar un comentario
Los comentarios serán publicados una vez sean aceptados por el moderador del blog, por lo que no aparecerán instantaneamente. No se publicará ningún comentario que pueda causar alarma innecesaria. El objetivo del blog es informar y dar opciones a quien lo consulte.